TD Cowen raised the firm’s price target on Ascendis Pharma to $156 from $133 and keeps a Market Perform rating on the shares. The firm increased 2024 Skytrofa estimates to $367M and in outyears given encouraging launch trajectory. Cowen also said the cost-cutting and strong uptake of Skytrofa are encouraging.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma, Vector Pharma FZCO enter exclusive distribution agreement
- Ascendis Pharma Introduces Vision 2030
- Specialised Therapeutics signs exclusive agreement with Ascendis Pharma
- Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
